Where does enVVeno Medical Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), enVVeno Medical Corporation ranks #31,559 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does enVVeno Medical Corporation hold?

enVVeno Medical Corporation holds 8 US utility patents granted between 2022 and 2025, spanning 2 technology areas.

What is enVVeno Medical Corporation's Innovation Score?

enVVeno Medical Corporation has an Innovation Score of 42.9 out of 100 (top 30% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is enVVeno Medical Corporation's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for enVVeno Medical Corporation.

What does claim depth mean for enVVeno Medical Corporation's patents?

enVVeno Medical Corporation's patents average 17.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the enVVeno Medical Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

enVVeno Medical Corporation

Q: What technology areas does enVVeno Medical Corporation focus on?

enVVeno Medical Corporation's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 8 patents. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 2 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, envveno ranks #31,559 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 2 technology areas.

#31,559
of 49,997 US assignees by volume: Top 30%
by Innovation Score (42.9/100): 17.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R31559 · US Corporation #31,559 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #31,559/49,997
PHOTO-FINISH eAffirm
CPC-NARROW A61F · 2 areas
INNOV-PAR 42.9/100
CLAIMS-RICH 17.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: eAffirm LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
enVVeno Medical · this assignee

43
3D Lighting… · lowest

7

What this shows envveno's Innovation Score is 42.9/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where envveno's grants concentrate

enVVeno Medical Corporation is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2024. By volume, envveno sits between eAffirm LLC and iBeam Materials, Inc..

envveno's three-year grant acceleration

enVVeno Medical Corporation shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

eaffirm

8
econnect

8
eero

8
efabless

8
i Proov

8
i-blason

8
i-calq

8
ibeam Materials

8
envveno Medical ◀

8

What this shows enVVeno holds 8 patents at rank #34,005, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near enVVeno

By rank, the assignees closest to #34,005 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in enVVeno's primary technology class.

envveno's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

enVVeno Medical Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	3	37.5%
2023	2	25.0%
2024	1	12.5%
2025partial year	2	25.0%

Which technologies does enVVeno Medical Corporation patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 8

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 5

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#31,559

of 49,997 tracked assignees

Innovation Score

42.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

enVVeno Medical Corporation's patent record in context - here's where to go next.

enVVeno Medical Corporation's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #31,559 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare enVVeno Medical Corporation against eAffirm LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.